| __timestamp | Bristol-Myers Squibb Company | CRISPR Therapeutics AG |
|---|---|---|
| Wednesday, January 1, 2014 | 5699000000 | 5114000 |
| Thursday, January 1, 2015 | 5001000000 | 13403000 |
| Friday, January 1, 2016 | 5002000000 | 31056000 |
| Sunday, January 1, 2017 | 4849000000 | 35845000 |
| Monday, January 1, 2018 | 4551000000 | 48294000 |
| Tuesday, January 1, 2019 | 4871000000 | 63488000 |
| Wednesday, January 1, 2020 | 7661000000 | 88208000 |
| Friday, January 1, 2021 | 7690000000 | 102802000 |
| Saturday, January 1, 2022 | 7814000000 | 102464000 |
| Sunday, January 1, 2023 | 7772000000 | 76162000 |
| Monday, January 1, 2024 | 8414000000 | 72977000 |
Unlocking the unknown
In the ever-evolving pharmaceutical and biotechnology sectors, understanding financial trends is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Bristol-Myers Squibb Company and CRISPR Therapeutics AG from 2014 to 2023. Bristol-Myers Squibb, a giant in the pharmaceutical industry, consistently reported higher SG&A expenses, peaking in 2022 with a 38% increase from 2014. In contrast, CRISPR Therapeutics, a pioneer in gene editing, showed a remarkable growth trajectory, with expenses increasing nearly 20-fold over the same period. This stark contrast highlights the differing scales and growth strategies of established pharmaceutical companies versus innovative biotech firms. As the industry continues to evolve, these insights provide a window into the financial strategies that drive success in the competitive landscape of healthcare.
Comparing SG&A Expenses: Eli Lilly and Company vs CRISPR Therapeutics AG Trends and Insights
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Bristol-Myers Squibb Company
Novartis AG or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Bristol-Myers Squibb Company or Zoetis Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and CRISPR Therapeutics AG
Halozyme Therapeutics, Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Alkermes plc and CRISPR Therapeutics AG: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Opthea Limited and CRISPR Therapeutics AG
Operational Costs Compared: SG&A Analysis of CRISPR Therapeutics AG and BioCryst Pharmaceuticals, Inc.